US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
List view / Grid view
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
11 May 2016 | By Victoria White, Digital Content Producer
Vekacia demonstrated efficacy and tolerability vs placebo in the treatment of active, severe vernal keratoconjunctivitis (VKC) in paediatric patients...
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
24 June 2015 | By
NICE has today published preliminary recommendations on ciclosporin (Ikervis) for treating severe keratitis in adults with dry eye disease...
25 March 2015 | By Victoria White
Santen Pharmaceutical has announced it received approval of the Marketing Authorisation Application (MAA) for Ikervis from the European Commission...
2 March 2015 | By Santen
Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency has accepted the company’s Marketing Authorization Application filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment...
4 December 2014 | By Santen
Following the launch of Santen in Italy in October 2014, Santen Italy s.r.l (Milano, Italy) (Santen) announces that Paolo Casati has been named General Manager of Santen Italy, effective November 21st, 2014...
4 November 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...
23 October 2014 | By Santen
Santen GmbH. announced the positive outcome of the Decentralized Procedure (DCP) for TAPTIQOM® in Europe...
16 October 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced its new wholly owned subsidiary in Italy...
13 May 2014 | By Merck
Merck announced that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products...